Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3708804 | 0.98 | TTR (0.31) | TTRTSHRSMN1; SMN2LMNAHPGD | |
| SCHEMBL3707666 | 0.98 | TTR (0.31) | TTRTSHRSMN1; SMN2LMNAHPGD | |
| SCHEMBL3701325 | 0.98 | TTR (0.31) | TTRTSHRSMN1; SMN2LMNAHPGD | |
| Lithium Ion SCHEMBL3707663 | 0.76 | PTGS1 (0.31) | — | |
| SCHEMBL27651919 | 0.74 | TTR (0.32) | TTRTSHRSMN1; SMN2LMNAPGAM1 | |
| SCHEMBL29443136 | 0.73 | TTR (0.31) | TTRTSHRSMN1; SMN2LMNAPGAM1 | |
| SCHEMBL29155974 | 0.73 | TTR (0.31) | TTRTSHRSMN1; SMN2LMNAPGAM1 | |
| SCHEMBL2527896 | 0.70 | POLB (0.34) | TTR | |
| SCHEMBL2828839 | 0.70 | ALDH1A1 (0.31) | — | |
| SCHEMBL29033432 | 0.70 | ACLY (0.41) | TSHRSMN1; SMN2HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110799190-B | Heterocyclic compounds | 卡都瑞恩医药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-110799190-A | Heterocyclic compounds | 卡都瑞恩医药有限责任公司 | 2020-02-14 | — | — | CN | disclosed |
| EP-2460789-B1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9079830-B2 | Method for producing biaryl compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-07-14 | — | — | US | disclosed |
| EP-2460789-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120123154-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123154-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | AKR7A2, AOC2, CBR1 | TTR 3752/4885TSHR 1160/4885SMN1; SMN2 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.